Concepedia
Statistics
Publications
49
Citations
2.7K
H-Index
28
Active since
1998
Affiliations
Center for Drug Evaluation and Research(Current)
Shanghai University of Traditional Chinese Medicine
Shuguang Hospital
Ningbo No. 2 Hospital
United States Food and Drug Administration
Hongshan Li is an author at Center for Drug Evaluation and Research specializing in medicine, pharmacology, and health sciences.
Top concepts
MedicinePharmacologyHealthImmunologyOncologyPathologyLiver PhysiologyMetabolic SyndromeHepatologyMetabolomics
Publications per year
1998–2024
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 286 citations · Full text
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 181 citations
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft
Chau-Ming Cheng, Stewart P. Johnson, Stephen T. Keir et al. · Molecular Cancer Therapeutics · 2005 · 172 citations
Molecular Characterization of the β-<i>N</i>-Acetylglucosaminidase of<i>Escherichia coli</i>and Its Role in Cell Wall Recycling
Qiaomei Cheng, Hongshan Li, Keith D. Merdek et al. · Journal of Bacteriology · 2000 · 166 citations · Full text
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 135 citations
Medicine, Pharmacology, Time Dependent Pharmacokinetics +8
1–5 of 49